Search Within

Michael Morris

  1. "Pat Zanzonico"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (3)
Groups
  1. Department of Medicine (7)
  2. GSK Faculty (7)
  3. Genitourinary Oncology Service (7)
  4. Medical Physics (7)
  5. Molecular Imaging and Therapy Service (7)
  6. Molecular Pharmacology and Chemistry Program Faculty (7)

More Groups

People
  1. Howard Scher (7)
  2. Pat Zanzonico (7)
  3. Steven Larson (7)
  4. John Humm (6)
  5. Bradley Beattie (5)
  6. Ronald Finn (4)

More People

Years
  1. 2019 (1)
  2. 2018 (1)
  3. 2014 (1)
  4. 2010 (1)
  5. 2004 (1)
  6. 2003 (1)

More Years

Publications
  1. Journal of Nuclear Medicine (5)
  2. Cancer Research (1)
  3. Molecular Pharmaceutics (1)
Publishers
  1. Society of Nuclear Medicine (5)
  2. American Association for Cancer Research (1)
  3. American Chemical Society (1)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pharmacokinetics and biodistribution of a [(86)Zr]Zr-DFO-MSTP2109A anti-STEAP1 antibody in metastatic castration-resistant prostate cancer patients
    Journal Article

    O'Donoghue, J. A.; Danila, D. C.; Pandit-Taskar, N.; Beylergil, V.; Cheal, S. M.; Fleming, S. E.; Fox, J. J.; Ruan, S.; Zanzonico, P. B.; Ragupathi, G.; more...
    Molecular Pharmaceutics (2019)

    Fulltext@MSK | Save
  • Reproducibility and repeatability of semiquantitative (18)F-fluorodihydrotestosterone uptake metrics in castration-resistant prostate cancer metastases: A prospective multicenter study
    Journal Article

    Vargas, H. A.; Kramer, G. M.; Scott, A. M.; Weickhardt, A.; Meier, A. A.; Parada, N.; Beattie, B. J.; Humm, J. L.; Staton, K. D.; Zanzonico, P. B.; more...
    Journal of Nuclear Medicine (2018)

    Fulltext@MSK | Save
  • Initial PET imaging and pharmacokinetic results from a Phase I/II study of Zr-89-labeled anti-STEAP1 antibody in metastatic castrate-resistant prostate cancer (mCRPC) patients
    Meeting Abstract

    Carrasquillo, J. A.; Danila, D. C.; Beylergil, V.; O'Donoghue, J. A.; Cheal, S. M.; Ruan, S. T.; Pandit-Taskar, N.; Fox, J. J.; Fleming, S. E.; Zanzonico, P. B.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Pharmacokinetic assessment of the uptake of 16β-18F-fluoro- 5α-dihydrotestosterone (FDHT) in prostate tumors as measured by PET
    Journal Article

    Beattie, B. J.; Smith-Jones, P. M.; Jhanwar, Y. S.; Schoder, H.; Ross Schmidtlein, C.; Morris, M. J.; Zanzonico, P.; Squire, O.; Meirelles, G. S. P.; Finn, R.; more...
    Journal of Nuclear Medicine (2010)

    Fulltext@MSK | Save
  • PET-based radiation dosimetry in man of 18F- fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer
    Journal Article

    Zanzonico, P. B.; Finn, R.; Pentlow, K. S.; Erdi, Y.; Beattie, B.; Akhurst, T.; Squire, O.; Morris, M.; Scher, H.; McCarthy, T.; more...
    Journal of Nuclear Medicine (2004)

    Fulltext@MSK | Save
  • Tumor localization of [18F]-Fluoro-Dihydro-testosterone (FDHT) versus [18F]-2-Fluoro-D-glucose (FDG) in patients with progressive, metastatic prostate cancer
    Meeting Abstract

    Larson, S. M.; Gunther, I.; Morris, M.; Beattie, B.; Akhurst, T. A.; Finn, R.; Pentlow, K.; Zanzonico, P.; Erdi, Y.; Humm, J.; more...
    Journal of Nuclear Medicine (2003)

    Fulltext@MSK | Save
  • PET-based radiation dosimetry in man of F-18-fluorodihydrotestosterone (FDHT), a new radiotracer for imaging prostate cancer
    Meeting Abstract

    Zanzonico, P.; Finn, R.; Pentlow, K. S.; Erdi, Y.; Beattie, B.; Humm, J.; Akhurst, T.; Squire, O.; Morris, M.; Scher, H.; more...
    Journal of Nuclear Medicine (2002)

    Fulltext@MSK | Save